Rami Hannoush, Ph.D., is a Venture Partner at Versant Ventures, where he leads life science investments and company creation initiatives. As an investor, he focuses on building and scaling early-stage biotech ventures, driving scientific strategy, and shaping high-impact partnerships with leading global pharmaceutical companies. Prior to joining Versant, Rami was a General Partner at Mubadala Capital, where he led investments across a portfolio of early- and late-stage biotech companies.
Rami also brings over two decades of hands-on drug development experience spanning large pharma and emerging biotech. He was the Chief Executive Officer and Co-Founder of EpiBiologics, where he also served as its founding Chief Scientific Officer. Earlier in his career, he held R&D leadership roles at Genentech, overseeing preclinical and translational strategies for advancing multiple drug candidates in immunology and oncology, with a strong focus on innovative drug modalities. He obtained his PhD in Chemistry from McGill University and did his postdoctoral training in chemical biology and cell biology at Harvard.